Can brain scans predict dementia risk in Late-Life depression?
NCT ID NCT07768098
First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time
Summary
This observational study follows adults aged 60 and older with late-life depression to see how the condition affects memory, dementia risk, and overall health over many years. Researchers will compare them with healthy peers of the same age and sex, using brain scans, blood tests, and memory assessments. The goal is to understand whether certain brain changes or biomarkers can predict how the illness will progress. No new treatment is being tested; the study relies on data from previous research and medical records.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify early warning signs of dementia and other serious outcomes in older adults with late-life depression, potentially guiding earlier interventions.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. The findings may not apply to all people with late-life depression, and the long follow-up may limit the number of participants who complete all assessments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 178 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants are adults aged 60 years and older who took part in one of the earlier related studies. This group includes people diagnosed with late-life depression as well as healthy adults of the same age and sex who serve as a comparison group. Participants are recruited from the existing cohort of these earlier studies, using their prior study data, medical records, brain scans, and blood samples. Participants will be asked to return for follow-up assessments, which can take place in the hospital or at their home.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures. * At least 18 years of age at the time of signing the Informed Consent Form (ICF). * Participants were included in the previous studies. Exclusion Criteria: * Not applicable, since participants who met any exclusion criteria were already excluded from the previous studies.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Late life depression (LLD) are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UZ Leuven
Leuven, Flanders, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.